Stockreport

How Monte Rosa's MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE's Risk-Reward Profile [Yahoo! Finance]

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF enzalutamide, was well-tolerated and produced positive clinical responses in heavily pretreated metastatic castration-resistant prostate cancer patients, and outlined pl [Read more]